HiCM-188

Human induced pluripotent stem cell-derived cardiomyocyte injection · HELP Therapeutics Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HiCM-188, covering 2026-04-03 to 2026-04-03. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart Failure (NYHA Class III-IV) [Phase 3]

See pricing